Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin

Figure 3 Comparisons of receiver operating characteristic curves of serum protein induced by vitamin K absence or antagonist-II for diagnosing early-stage hepatocellular carcinoma in different subgroups. A: For all early-stage patients; B: Between viral and nonviral subgroups; C: Between alkaline phosphatase ≤ 1 × upper limit of normal (ULN) and alkaline phosphatase > 1 × ULN subgroups; D: Between total bilirubin (TBIL) ≤ 1 × ULN and TBIL > 1 × ULN subgroups; E: Between aspartate aminotransferase (AST) ≤ 1 × ULN and AST > 1 × ULN subgroups. ULN: Upper limit of normal; TBIL: Total bilirubin; HCC: Hepatocellular carcinoma; AUC: Area under the receiver operating characteristic curve; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase.